What's Happening?
Acurex Biosciences, a biotechnology company based in San Carlos, California, has been awarded a grant from Aligning Science Across Parkinson’s (ASAP) in collaboration with The Michael J. Fox Foundation for Parkinson’s Research. This grant will support
a multi-year research collaboration aimed at developing a novel therapeutic approach for Parkinson’s disease. The project will involve leading researchers, including Dr. Tim Greenamyre from the University of Pittsburgh, who has been at the forefront of Parkinson’s research. The focus of the research is on an enzyme called 15-lipoxygenase (15-LO), which is believed to play a role in the cellular damage associated with Parkinson’s disease. Acurex aims to develop small-molecule medicines that can block 15-LO, potentially protecting nerve cells and slowing disease progression.
Why It's Important?
This development is significant as it represents a potential shift in the treatment of Parkinson’s disease, which affects nearly 10 million people worldwide. Current treatments primarily manage symptoms without addressing the underlying disease progression. Acurex’s approach targets the biological mechanisms of the disease, offering hope for more effective treatments. The grant and collaboration with top researchers could accelerate the development of these new therapies, potentially leading to clinical trials and, eventually, new treatment options for patients. This could have a profound impact on the quality of life for those affected by Parkinson’s and may also influence future research directions in neurodegenerative diseases.
What's Next?
The collaboration will focus on understanding how 15-LO contributes to the loss of brain cells in Parkinson’s disease and identifying ways to interrupt this process. Acurex plans to advance its lead drug candidates toward human clinical trials. The company is also preparing to raise Series A funding to support these efforts. The success of this research could lead to significant advancements in the treatment of Parkinson’s disease and potentially other neurodegenerative disorders.
